The agreements allow distribution in the following countries: under this agreement, Cipla will be responsible for the marketing and distribution of Roche Pharma`s leading brand-name oncology drugs, namely trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova). As part of the agreement, Cipla will have the right to manufacture the API and finished product and market it under cipla`s brand in 127 countries, including India and South Africa. Cipla will have the know-how of Gilead Sciences, Inc. to manufacture the API and finished product on a commercial scale. Cipla`s significant geographic and commercial presence will help make this treatment accessible to more patients and markets. Under the licensing agreements, companies have the right to obtain technology transfer from Gilead`s manufacturing process to Remdesivir so that they can increase production faster. Licensees also set their own prices for the generic drug they produce. Licenses are free of charge until the World Health Organization declares the end of the health emergency of international importance with respect to COVID-19 or until a pharmaceutical product other than remdesivir or a vaccine is authorized for the treatment or prevention of COVID-19, whichever is earlier. The company`s recent agreement aims to increase global access to life-saving therapies and diagnostic infrastructure for people in distress. Indian pharmaceutical company Cipla has signed a licensing agreement with Multi G in Belgium for the distribution of its Covi-G Covid-19 antibody kit in Europe and other emerging countries. Roche and Cipla had already entered into a similar agreement in February 2018 for the promotion and distribution of tocilizumab (Actemra) and other products.
Founded in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generic medicines and deepening our portfolio in our domestic markets, India, South Africa, North America, as well as important regulated and emerging markets. Our strengths in the segments of the respiratory tract, antiretrovirals, urology, cardiology, anti-infective and SNS are known. Our 46 production sites around the world produce more than 50 pharmaceutical forms and more than 1500 products equipped with state-of-the-art technology platforms to serve our more than 80 markets. Cipla occupies the 3rd. Place in the pharmaceutical sector in India (IQVIA MAT Mar`20), the 3rd largest private pharmaceutical market in South Africa (IQVIA MAT Mar`20) and is one of the most distributed generic readers in the United States. For more than eight decades, moving a difference for patients has inspired every aspect of Cipla`s work. Our paradigm-changing offering of triple antiretroviral therapy for HIV/AIDS at less than a dollar a day in Africa in 2001 is widely recognized as it has helped place inclusion, accessibility and accessibility at the heart of the HIV movement. . . .